The Food Safety and Standards Authority of India (FSSAI) has sought clarifications from Nestle India regarding its claims related to ‘5HMOs’ and ‘Whey Protein’ in infant nutrition products. This latest development, reported by The Hindu, follows the regulatory body’s initiation of legal action against the company on September 19, 2026, over alleged non-compliance in its infant food products.

On September 19, both Livemint and The Hindu reported FSSAI’s decision to initiate legal proceedings against Nestle India. The action specifically targeted promotional claims made for two of Nestle’s infant formula brands, NAN Excella Pro and Lactogen Pro. Nestle India responded the same day, asserting its full compliance with all applicable FSSAI regulations and confirming it was engaging with the authority. This consistent defense was reiterated today, according to Livemint, with the company maintaining adherence to all laws even as the FSSAI continues its scrutiny.

The FSSAI’s persistent focus on specific ingredient claims, such as ‘5HMOs’ (Human Milk Oligosaccharides) and ‘Whey Protein’, shows stricter regulation for food manufacturers, particularly those in sensitive categories like infant nutrition. For food technology startups and those developing health-focused products, this ongoing scrutiny of a major player like Nestle India offers a clear lesson. Marketing claims, especially those related to nutritional benefits or specific ingredients, need strong scientific evidence and must strictly adhere to regulatory guidelines from inception. The FSSAI is actively seeking detailed clarifications on the scientific basis and communication of these claims to the public.

Implications for Indian Startups

The FSSAI’s action against Nestle India, and the company’s repeated defense of compliance, outlines a key area for emerging Indian startups in the food and health tech sectors. Building trust with consumers, particularly in products for vulnerable populations, requires absolute transparency and verifiable data behind every promotional statement.

Startups often move quickly to innovate and capture market share, but this case demonstrates the necessity of embedding regulatory compliance into product development and marketing strategies from the earliest stages. Any company developing products with specific health claims, be it for immunity, gut health, or infant development, must anticipate and prepare for detailed inquiries from regulatory bodies like the FSSAI. This means:

  • All claims, especially those referencing specific compounds or physiological benefits, must be backed by credible, peer-reviewed scientific data. The FSSAI’s focus on ‘5HMOs’ and ‘Whey Protein’ suggests a granular level of review.
  • Marketing materials, packaging, and digital advertisements must be reviewed by legal and regulatory experts to ensure they align with FSSAI (and other relevant) guidelines. Ambiguity or overstatement can trigger legal action.
  • Companies should have clear channels and processes for engaging with regulatory bodies. Nestle India’s repeated statement about “continuing to engage” with FSSAI suggests an ongoing dialogue that helps manage regulatory challenges.

The precedent set by actions against established companies often filters down to smaller players. While Nestle India has the resources to manage legal challenges, a startup facing similar scrutiny could see its resources diverted, reputation damaged, and growth significantly hindered. The current regulatory environment demands that innovation in food tech is paired with an equally strong commitment to compliance and ethical marketing.

The sustained attention from FSSAI on Nestle India’s infant nutrition products, particularly concerning the substantiation of ingredient claims like ‘5HMOs’ and ‘Whey Protein’, shows the importance of regulatory adherence for all businesses operating in the food sector. This ongoing scrutiny indicates the FSSAI’s intent to enforce stringent standards for product claims and consumer communication.

What specific claims did FSSAI question?

The FSSAI sought clarifications from Nestle India regarding its claims related to ‘5HMOs’ and ‘Whey Protein’ in infant nutrition products.

Which Nestle India products are under scrutiny?

The FSSAI‘s legal action and clarifications concern Nestle India’s infant nutrition products, specifically NAN Excella Pro and Lactogen Pro.

What has been Nestle India’s response to the FSSAI action?

Nestle India has consistently stated that its infant nutrition products fully comply with all applicable FSSAI regulations and that the company continues to engage with the authority.

Compiled by Launch91 Desk from the sources linked above. More about Launch91.